Abcellera Biologics Inc (ABCL)vsModerna Inc (MRNA)
ABCL
Abcellera Biologics Inc
$12.65
-0.08%
HEALTHCARE · Cap: $3.39B
MRNA
Moderna Inc
$182.56
+5.56%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 3267% more annual revenue ($2.23B vs $66.17M). MRNA leads profitability with a -141.4% profit margin vs -248.8%. ABCL earns a higher WallStSmart Score of 27/100 (F).
ABCL
Avoid27
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.4%
Fair Value
$6.87
Current Price
$12.65
$5.78 discount
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$182.56
$47.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Earnings expanding 45.9% YoY
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Distress zone — elevated risk
ROE of -15.3% — below average capital efficiency
Revenue declined 76.3%
Negative free cash flow — burning cash
Trading at 10.8x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABCL
The strongest argument for ABCL centers on Debt/Equity, EPS Growth.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ABCL
The primary concerns for ABCL are Altman Z-Score, Return on Equity, Revenue Growth.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ABCL carries more volatility with a beta of 1.32 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
ABCL generates stronger free cash flow (-36M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABCL scores higher overall (27/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abcellera Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?